Medela Introduces Pump In Style® Pro: Hospital-Grade Innovation Designed for Real Life
The new pump blends clinically proven performance with modern convenience, offering moms reliable support and continuity of care from hospital to home
Pump In Style® Pro
Pump In Style® Pro
McHenry, Illinois, June 17, 2025 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms worldwide and the #1 brand in hospitals1, today announced the launch of the Pump In Style® Pro, the latest evolution in its trusted product line. Developed from five years of insights and feedback, the new and improved Pump In Style® Pro delivers hospital-grade performance in a compact, easy-to-use design, offering moms seamless continuity of care from hospital to home.
To develop the most efficacious pump on the market, Medela grounded its approach in research combining clinical evidence with real-world insights. Input from hundreds of healthcare professionals, its community of moms, quantitative survey research and focus group shaped every step of the process. By addressing common pain points and pitfalls associated with other pumps, Medela designed a solution that features a clinically proven pumping pattern modeled after the #1 breast pump used in hospitals, the Medela Symphony®. The result is a pump that empowers moms to express milk more effectively and confidently at home.
'At Medela, we understand that every mom's breastfeeding journey has many stages and the adjustment from hospital to home can be challenging and stressful without the right support. Our goal is to make that transition as seamless as possible with the new Pump In Style Pro®,' said Kelley Evans, EVP and Head of Commercial, Americas, at Medela. 'This redesigned pump combines the power of our hospital-grade technology with a design that's simple, comfortable, and built for everyday life.'
Key features of the new Pump In Style® Pro include:
Hospital-Grade Performance at Home: Features a clinically proven pumping pattern, similar to Medela's hospital pump Symphony, for effective milk expression, more comfort and a stress-free transition home.
Pumping Level & Mode Indicators: 16 level indicators and pumping mode indicators allow moms to fine tune their comfort and take control of each pumping session.
Lightweight & Compact: Weighs less than 2 pounds, making it easy to transport and ideal for use on the go.
11.8%2 More Milk: Clinically Proven Breast Shield Technology to increase milk volume.
Closed System & Easy Cleaning: Dishwasher safe parts and backflow protector.
The Pump In Style® Pro is now available through insurance and WIC. For more information on coverage and purchasing options, please see here.
Additional downloadable materials, including a factsheet, visual assets, and video content, are available via the Medela media portal.
About MedelaThrough advancing research, observing natural behavior and listening to our customers, Medela turns science into care while nurturing health for generations. Medela supports millions of moms, babies, patients and healthcare professionals in more than 100 countries all over the world. As the healthcare choice for more than 6 million hospitals and homes across the globe, Medela provides leading research-based breast milk feeding products, healthcare solutions for hospitals, and clinical education. Medela is dedicated to building better health outcomes, simplifying and improving life, and developing breakthroughs that help moms, babies and patients live their life to the fullest. For more information, visit www.medela.com.
(1) Sales and distribution in maternity wards and NICUs, 2023 & 2024
(2) Sakalidis VS, et al. Breast shield design impacts milk removal dynamics during pumping: A randomized controlled non-inferiority trial. Acta Obstet Gynecol Scand. 2020.
Attachments
Pump In Style® Pro
Pump In Style® Pro
CONTACT: medela@cerconebrown.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
10 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
10 hours ago
- Business Upturn
ImpactLife shares highlights from World Sickle Cell Disease Awareness Day event
Davenport, Iowa, June 20, 2025 (GLOBE NEWSWIRE) — ImpactLife hosted a special event at its Davenport, Iowa headquarters to recognize World Sickle Cell Disease Awareness Day as part of local celebrations of the Juneteenth federal holiday. The Juneteenth holiday — commemorating the emancipation of enslaved people in the United States — is also recognized as World Sickle Cell Awareness Day with the goal to increase public knowledge of sickle cell disease and the challenges experienced by patients and caregivers. Community members and blood center employees gathered on Thursday, June 19, to learn about the importance of blood transfusions in providing supportive care for sickle cell patients and to hear personal experiences from those who live with sickle cell disease, or who have lost loved ones to the genetically inherited blood disorder. Speakers included Beleta Rush, who shared writings and experiences from the lives of her two daughters, Lynn and Bobbie. View and download video clips from the event, below, or on the ImpactLife web site. Dr. Meredith Parsons, Clinical Assistant Professor of Pathology from University of Iowa, provided an overview on sickle cell disease, how it affects patients, and the importance of having appropriately matched units of blood available for patients who are likely to receive multiple rounds of blood transfusions throughout their lives. Shyneeta Rush, Supervisor, Donor Services, described the blood center's Red4Life program and efforts by the blood center to identify donors who are an appropriate match for sickle cell disease patients. Cheryl Easley, of the ImpactLife donor scheduling team, helped organize the event, and recognized sickle cell 'Warriors In Battle' as well as 'Winged Warriors,' who have passed after living with the disease throughout their lives. Lamour Bluitt has two sisters living with sickle cell disease, and has authored a book on their experiences, A Child Born with Sickle Cell: the Untold Secret. About Sickle Cell Disease Sickle dell disease is an inherited blood disorder that affects red blood cells. It is the most common hereditary disorder and currently affects more than 100,000 Americans, predominantly people of African descent. The red blood cells in patients with sickle cell disease can become 'sickled' in shape, which can cause the cells to become stuck in small blood vessels. Patients can experience pain and anemia and are at increased risk for strokes and other types of organ damage. When patients experience a sickle cell crisis, red cell transfusion is a major form of therapy to relieve symptoms. Patients with sickle cell disease frequently receive transfusions of red blood cells to help treat symptoms of a sickle cell crisis. But finding appropriately matched units for sickle cell disease patients is a challenge for blood providers. With more frequent blood transfusions, patients with sickle cell disease can develop antibodies that are directed against red blood cell antigens. This process, called alloimmunization, makes it important for patients to receive antigen-negative blood types that are more generally found in donors of African descent. To help increase the diversity of the blood center's donor base, ImpactLife has created a donor program called Red4Life. Under Red4Life, the blood center identifies and recruits donors who may be an appropriate antigen match for patients with sickle cell disease. These donors are then invited to join the Red4Life program and receive special donor rewards and additional points to use in the ImpactLife Donor Loyalty Store. (Learn more at About ImpactLife ImpactLife's mission is to save lives by engaging donors, supporting partners, and advancing medicine. Founded in 1974, ImpactLife supplies blood products and services to hundreds of hospitals, emergency services organizations, clinical researchers, and other blood centers throughout Iowa, Illinois, Wisconsin, and Missouri. The nonprofit blood provider is ranked among the leading 12 blood suppliers in the United States. For more information on current blood inventory levels, our donor promotions, and more, see and find us @impactlifeblood on Facebook, X, Instagram, Threads, YouTube, and LinkedIn. Attachments Beleta Rush ImpactLife – World Sickle Cell Disease Awareness Day group photo Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
10 hours ago
- Business Upturn
Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) — Saudi Arabia has concluded its landmark debut at the BIO International Convention 2025, having signed more than a dozen partnerships, launched a national biotech accelerator program with Biolabs and established the Kingdom as a global hub for life sciences. Over four days, Saudi delegates showcased an ecosystem ready for collaboration across scientific discovery, clinical research, and advanced therapeutics. The Kingdom's presence spanned the entire biotech value chain – from early research to manufacturing, from regulatory frameworks to commercialization pathways. 'Saudi Arabia is stepping into biotech with intention and scale,' said His Excellency the Vice Minister of Health for Planning and Development, Eng. Abdulaziz AlRamaih. 'Biotech sits at the intersection of our health transformation and economic ambition, and we are investing with that dual mandate in mind.' Partnerships and Programs Take Center Stage Throughout the week, Saudi Arabia hosted one of the most active national pavilions at the conference, convening more than 25 entities across government, research, investment and innovation. More than a dozen new memoranda of understanding were signed with international partners, including leaders in genomics, AI-enabled diagnostics, gene therapy, and biomanufacturing. The Ministry of Health also formally launched its national biotech accelerator program in collaboration with BioLabs, welcoming an inaugural cohort of eight Saudi-founded biotech startups in areas ranging from protein engineering to precision genomics. The launch event brought together venture capitalists, researchers, and biotech executives to discuss the Kingdom's innovation momentum. The Kingdom's Super Session at BIO 2025 featured senior representatives from the Ministry of Health (MoH), the Saudi Food and Drug Authority (SFDA), the Saudi National Institute for Health (SNIH), the King Abdullah International Medical Research Center (KAIMRC), the King Faisal Specialist Hospital and Research Centre (KFSH&RC), and the Public Investment Fund (PIF). The panel revealed how Saudi Arabia is coordinating across policy, clinical infrastructure, and public investment to create a biotech ecosystem built for scale and scientific depth. In parallel, the delegation held more than 50 one-to-one meetings with global biotech firms and visited U.S. innovation hubs to explore collaboration in research, manufacturing, and translational medicine. The Kingdom also participated in a dedicated gathering for Saudi research talent studying in the United States, underscoring the Kingdom's long-term commitment to human capital in health and life sciences. Advancing Genomics and Genetic Medicine The Kingdom's ambition in genomics also drew significant interest. Through the Saudi Genome Program, the Kingdom has developed one of the region's most comprehensive population-specific genomic datasets, paving the way for earlier diagnosis, localized drug development, and new therapeutic approaches for inherited diseases. National screening efforts – led by Saudi Arabia's Public Health Authority, Weqaya – are expanding access to genetic risk detection through prenatal and newborn programs. Institutions like KFSH&RC and KAIMRC continue to drive forward clinical trials and translational research, supporting a growing pipeline of personalized treatments rooted in real-world data. Already, over 130 peer-reviewed publications have leveraged Saudi genomic data to inform rare disease research and advance precision diagnostics. The Kingdom's cell and gene therapy readiness now spans regulation, clinical trials, and talent development, with the Saudi Food and Drug Authority's fast-track approval of advanced therapies positioning it as one of the world's most agile regulators. A Platform for the Future Under the National Biotechnology Strategy, with the continued support of HRH Prince Mohammed bin Salman, Crown Prince and Prime Minister, Saudi Arabia is making biotech central to its national transformation, and the health and economic prosperity of its people. The Kingdom concludes BIO 2025 with a clear message: Saudi Arabia is open for collaboration, primed for innovation, and committed to lasting partnerships. About Saudi Biotech The Kingdom of Saudi Arabia was proud to debut its first-ever national pavilion at BIO International, being held in Boston June 16-19, 2025. Rooted in Vision 2030, this initiative showcased a fully integrated life sciences ecosystem – combining a future-ready lifestyle, world-class research institutions, streamlined regulation, and digital infrastructure built for speed, scale, and scientific impact. The Kingdom offers a seamless environment for biotech innovation with fast-track clinical trial approvals, robust regulatory alignment via its ML4-designated Food and Drug Authority, and nationwide digital platforms like NPHIES and the world's largest Virtual Hospital. Saudi Biotech brings together the Kingdom's leading health and science entities, including the Ministry of Health, Saudi Food and Drug Authority, Saudi National Institute of Health, Public Health Authority, and the Saudi Health Council, all of whom play vital roles in enabling a regulatory environment that supports clinical innovation. It also features institutions powering translational research and IP protection, such as the Research, Development and Innovation Authority, King Faisal Specialist Hospital and Research Centre, King Abdulaziz City for Science and Technology, King Abdullah University of Science and Technology, and the King Abdullah International Medical Research Center. Funding and investment facilitators were also present, including the Ministry of Investment, Ministry of Industry and Mineral Resources, and the Saudi Business Center, alongside localization powerhouses like Lifera, Lean, and the Public Investment Fund. Visitors had the opportunity to explore how talent and livability are central to the Kingdom's strategy through participation from the Royal Commission for Riyadh City and the Premium Residency Center. Finally, NEOM showcased the Kingdom's most ambitious vision – a purpose-built frontier for biotech, precision medicine, and future health. Visit to learn more. Contact:Saudi Biotech [email protected]
